Sign In
Buy ANAB
$51.24
-0.0200 (-0.0390%)
At Close: Jun 03, 2026
Anaptys Announces $100 Million Stock Repurchase Plan
04:00am, Friday, 21'st Nov 2025
SAN DIEGO, Nov. 21, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that its
Anaptys Initiates Litigation Against Tesaro, a GSK Subsidiary
03:50am, Friday, 21'st Nov 2025
SAN DIEGO, Nov. 21, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, announced it has filed a
GSK unit sues AnaptysBio in row over Jemperli rights
02:36am, Friday, 21'st Nov 2025
GSK PLC (LSE:GSK, NYSE:GSK) has stepped up a dispute over rights to its fast-growing cancer drug Jemperli by having its US subsidiary Tesaro sue AnaptysBio in the Delaware Court of Chancery. Tesaro i
AnaptysBio: Maintaining 'Hold' As RA Program Still In Play With ANB033 Advancement
07:30am, Thursday, 13'th Nov 2025
AnaptysBio receives a "Hold" rating after discontinuing rosnilimab for ulcerative colitis, saving $10 million but maintaining focus on rheumatoid arthritis. ANAB plans to advance rosnilimab for RA, wi
AnaptysBio To Save $10 Million After Discontinuing Ulcerative Colitis Study
12:30pm, Monday, 10'th Nov 2025
AnaptysBio Inc. (NASDAQ:ANAB) on Monday released data from the Phase 2 trial of rosnilimab for moderate-to-severe ulcerative colitis.
Rosnilimab was safe and well tolerated with similar adverse event rates vs. placebo Observed expected pharmacology, including ~90% depletion of pathogenic T cells, however lack of adequate efficacy at
AnaptysBio, Inc. (ANAB) Surpasses Q3 Earnings and Revenue Estimates
06:50pm, Tuesday, 04'th Nov 2025
AnaptysBio, Inc. (ANAB) came out with quarterly earnings of $0.52 per share, beating the Zacks Consensus Estimate of a loss of $1.06 per share. This compares to a loss of $1.14 per share a year ago.
Anaptys Announces Third Quarter 2025 Financial Results and Provides Business Update
04:15pm, Tuesday, 04'th Nov 2025
Announced intent to separate biopharma operations from substantial royalty assets by YE 2026 Phase 2 top-line data through Week 12 for rosnilimab, a pathogenic T cell depleter, in ulcerative colitis o
Anaptys Announces Participation in November Investor Conferences
04:15pm, Tuesday, 04'th Nov 2025
SAN DIEGO, Nov. 04, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Dani
Anaptys Announces New Positive Phase 2b Trial Results for Rosnilimab in Rheumatoid Arthritis at ACR Late-Breaking Oral Presentation
09:15am, Wednesday, 29'th Oct 2025
SAN DIEGO, Oct. 29, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced late-brea
AnaptysBio, Inc. (ANAB) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
11:01am, Tuesday, 28'th Oct 2025
AnaptysBio (ANAB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AnaptysBio, Inc. - Special Call
05:37am, Wednesday, 15'th Oct 2025
AnaptysBio, Inc. - Special Call Company Participants Daniel Faga - President, CEO & Director Martin Dahl - Senior Vice President of Research John Kwon Paul Lizzul - Chief Medical Officer Conference Ca
SAN DIEGO, Oct. 13, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that comp
AnaptysBio Charts Path To Split Into Two Public Companies By 2026
01:59pm, Tuesday, 30'th Sep 2025
AnaptysBio, Inc. (NASDAQ:ANAB) announced on Tuesday that it plans to explore separating its business into two independent, publicly traded companies.
AnaptysBio, Inc. - Special Call
09:27pm, Monday, 29'th Sep 2025
AnaptysBio, Inc. - Special Call Company Participants Daniel Faga - President, CEO & Director Dennis Mulroy - Chief Financial Officer Conference Call Participants Anupam Rama - JPMorgan Chase & Co, Res
